Income Statement Presentation 2023

2022: Pharmaceuticals Division Core OP growth driven by higher gross profit, higher ROOI and lower G&A Roche 2022 CHFm % sales 2022 vs. 2021 CER growth Sales 45,551 100.0 2% Royalties & other op. inc. 3,077 6.8 3% Cost of sales -9,262 -20.3 -2% COGS+PC: -7% M&D -6,657 -14.6 2% R & D -12,096 -26.6 1% G & A -1,441 -3.2 -6% Admin: -2% Core operating profit 19,172 42.1 5% +3% in CHF CER=Constant Exchange Rates; ROOI-royalties and other operating income; COGS=costs of goods sold; PC-period costs 21 21

View entire presentation